At a workshop at The Bridge Summit 22-23 August, Medicon Village and Research Institutes of Sweden (RISE) invites you to explore how business models of healthcare can change based on disruptive technologies. The organizers aim to shed light on how cell and gene therapy, or advanced therapy medicinal product (ATMP), could become available to the general population – irrespective of economic situation.
The Bridge Summit is an annual two-day summit, this year in Copenhagen, on the two themes Good Health and Well-being and, Sustainable Cities and Communities. Workshops are on parts of the agenda – one within cell and gene therapy.
- The key question is to find the right technology for the right disease and ensure we can produce cells with a specific property in a cost effective way. Apart from cells, new therapies on ATMPs use also genes and scaffolds, explains Marcel Frankowiack, innovation manager for cell therapy at RISE.
Cell and gene therapy are redefining what may be possible to treat and cure, and ample work is aiming to turn cell and gene therapy research into treatments in clinical trials. But while clinical trials show encouraging results, affordable technologies and scaling production currently limit the use of future cell and gene therapies in health care. Therefore, a workshop at The Bridge Summit in August will address how cell and gene therapy could become a treatment for the general population through new business models based on disruptive technology, that is, a radical technology that shakes up the industry or creates a completely new one.
- I´m hoping for an exploration of an exchange of thoughts, but the challenge is that, by the development of new therapies, with people from different occupational backgrounds, says Marcel Frankowiack. We need to think outside the box. The traditional thoughts on how to develop meds does not entirely work within the ATMP field. Therefore you need to gather different views and jointly develop ideas between healthcare, patient organizations, counties who will pay for the treatment, and the industry.
ATMP are meds based on genes, cells or tissues according to defined scientific criteria.
- We hope to initiate discussions to gain a better understanding of improved business models based on disruptive technologies. In a wider perspective we hope to create an arena for discussions in the region, since this will help us in our intention to create a cell and gene therapy centre at Medicon Village, says Anette Orheim, communications director at Medicon Village.
Medicon Village intends to establish a Centre for Advanced Therapies with initial focus on cell and gene therapy, mainly together with Region Skåne and Lund University. The trio will tie existing infrastructure with cutting edge academic and industrial competence to leverage process development and commercial production.
- We hope that not only the stakeholders we currently collaborate with in this field will join the workshop, but that they also will bring some of their skilled contacts. We also hope to gain input from international conference participants to broaden our perspective, Anette Orheim points out.
- The Summit welcomes societal actors who own the needs, researchers who sit on the latest technologies, and entrepreneurs, who really get things done – the big companies and the small, says Jonas Klevhag, process manager at Altitude Meetings, organizers of The Bridge Summit.
The mix of leading participants gathers on 22 -23 August to network, disrupt and to inspire. Business and science meets in a Summit that offers a platform to spur innovation and solve challenges addressed in the two themes.
By: Tanja Jensen, Science writer